Pharma Will Need To Embrace More Inward-Looking China
Policies To Affect Market Access?
Executive Summary
The world’s second-largest economy is fast moving away from reforms and open to a "dual circulation" model, focusing on domestic market consumption while reducing export-driven production. Executives and investors shared views at a conference on whether multinational pharma firms are still welcome in China and what opportunities may lie in the drastic policy shift.
You may also be interested in...
APAC Podcast: Policies Play Out Against Pandemic, Corporate Activity Remains Strong
Join the Asia Pacific content team for a wide-ranging overview and analysis of recent developments across China, India, South Korea and Japan in the policy, regulatory, commercial and vaccines spaces over the past few months.
Evotec, Takeda Execs’ Big Picture Insights To Shape India’s R&D Push
Evotec's CEO and Takeda’s president of R&D provide insights around how India could shape its efforts to accelerate biopharma innovation. Backing the right technologies, fostering a culture to "stop losses" early on for projects that don't work and learning from China’s overhaul of its healthcare system were among the key takeaways.
Winter Olympics Test China's 'Zero COVID' Limits, Treatment Constraints
Amid China’s increasingly inward-looking and dual circulation economic policies, the Beijing Winter Olympics provide rare insight into policymakers’ handling of a global event.